Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Dibotatug in Adults With Bone Marrow Failure Syndromes

NCT07712562 is registered in ClinicalTrials.gov with Dren Bio as lead sponsor.

NCT NCT07712562
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07712562 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Dibotatug in Adults With Bone Marrow Failure Syndromes
Lead sponsor
Dren Bio
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
August 31, 2026
Completion date
October 31, 2030
Enrollment
60 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

aplastic anemias, bone marrow failure syndromes, non-severe aplastic anemia, severe aplastic anemia (saa), severe aplastic anemia, refractory, severe aplastic anemia, relapse